Health
New drug reduces tumor volume and pain in patients with neurofibromatosis type 1 – News-Medical.Net
Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children’s Hospital of Philadelphia (CHOP) as part of the…
Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children’s Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1).
The results of the Phase 2 clinical trial, co-chaired by Michael J. Fisher, MD at CHOP, were published recently in Nature Medicine.
“This is the second…
-
Noosa News18 hours agoYoung voices shape Sunshine Coast’s future
-
Business18 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News16 hours agoAnother All-Star Cast, Another Tale of Family Chaos: The Trailer for Wes Anderson’s ‘The Phoenician Scheme’ Is Here
-
Business14 hours agoshould I buy hedged or unhedged ASX US-focused ETFs?